PPARG

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Neoplasm, Carcinoma, Therapy, Flare, ADC, UC, Biotechnology, Knowledge, ASCO, PPARG, Cancer, Factorization of polynomials, PD, Human, Safety, Biomarker, TME, Pharmacokinetics

CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced a poster presentation outlining the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG, at the 2024 ASCO Genitourinary Cancers Symposium taking place from January 25-27, 2024 in San Francisco, CA.

Key Points: 
  • "FlareTx has built a robust body of preclinical evidence that supports investigation of FX-909 in clinical trials in patients," said Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of Flare Therapeutics. "
  • Results shown to date reveal that FX-909 eradicates tumors in urothelial cancer (UC) animal models at low oral doses.
  • Exploratory objectives include the evaluation of patient selection biomarkers from tissue and blood samples and association with clinical outcomes.
  • In the US, approximately 10 sites are planned for Phase 1A and 12-15 sites for Phase 1B.

Flare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Cancer, AACR, Patient, Therapy, Factorization of polynomials, American Association for Cancer Research, Flare, Gene silencing, PPARG, Pharmaceutical industry, Medical imaging, Communications satellite, UC

Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Key Points: 
  • Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
  • ET
    Flare is advancing FX-909 into the clinic in patients with advanced urothelial cancer (UC).
  • FX-909 is a potent, selective, small molecule inhibitor of the PPARG lineage transcription factor.
  • In pre-clinical models, FX-909 displays meaningful PPARG target gene silencing in UC cell lines as well as tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.

Flare Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Third Rock Ventures, Factor X, Biotechnology, Therapy, Conference, Flare, PPARG, Cancer, Piper Sandler Companies, Pharmaceutical industry

Flare Therapeutics , a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at 9:30 a.m.

Key Points: 
  • Flare Therapeutics , a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at 9:30 a.m.
  • ET on Thursday, December 1, 2022 at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY.
  • Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus in precision oncology.
  • Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 28, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, IND, RXRA, Biotechnology, Drug discovery, Cancer, Retinoid X receptor alpha, Flare, Disease, Recurrence, Squamous cell carcinoma, Peroxisome proliferator-activated receptor gamma, Inflammation, Senior, HIV disease progression rates, Neurology, Neoplasm, Patient, Bladder cancer, FGFR3, RWD, Lists of diseases, Third Rock Ventures, Therapy, UC, Investigational New Drug, Knowledge, Incidence, Factor X, Pharmaceutical industry, PPARG, Biology

Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.

Key Points: 
  • Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.
  • This disease has high rates of recurrence and the five-year survival rate is approximately 5% in metastatic cases.
  • The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC patients.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Lists of diseases, RXRA, Disease, Therapy, Squamous cell carcinoma, IND, Factor X, Neoplasm, Biotechnology, Bladder cancer, Patient, Biology, Inflammation, Cancer, Drug discovery, Neurology, Incidence, Breast, Retinoid X receptor alpha, Prostate cancer, Recurrence, Third Rock Ventures, Gene silencing, Gene, Pharmaceutical industry, Medical imaging, PPARG, Flare, UC

Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.

Key Points: 
  • Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.
  • In preclinical models, FTX-6746 demonstrated a favorable therapeutic profile, suppressing PPARG target genes with durable tumor regression at well-tolerated doses.
  • Flare is poised to transition to a clinical-stage company early next year with our lead molecule in the PPARG program.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.